Givlaari (Givosiran Sodium) Patent Expiration, LOE Window & CMS Spending

Givlaari (Givosiran Sodium) by Alnylam Pharmaceuticals: FDA Orange Book core substance LOE 2034-10-03, 0 AB generics, $39.9M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAlnylam Pharmaceuticals
FDA Application & PathwayN212194 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2034-10-03
Last Listed Patent or Exclusivity Date2034-10-03
Orange Book Patents (*PED Extensions)8 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$39.9M
2024 Medicare Part D Spend$20.9M
2024 Medicaid Spend$18.9M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Alnylam Pharmaceuticals across sibling Meru public-data platforms.